Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 5,908

Cell-Based Dairy Bio-Products For Health & Nutrition — Dr. Aletta Schnitzler, Ph.D. — CSO — Turtletree Labs

Dr. Aletta Schnitzler, PhD. is the Chief Scientific Officer at TurtleTree Labs (https://turtletree.com/) where she leads the R&D teams and spearheads an innovation roadmap to bring nutritious cell-based dairy and meat alternatives to market.

TurtleTree is a biotech company dedicated to producing a new generation of nutrition—one that’s better for the planet, better for the animals, and better for people everywhere. Utilizing its proprietary, cell-based technology, the company is creating “better-for-you” milk ingredients sustainably and affordably, with benefits that extend beyond the dining table and into the heart of humanity.

Previous to joining TurtleTree, Dr. Schnitzler co-founded Merck KGaA’s Cultured Meat Innovation program and directed technology development to advance platforms enabling rapid development, validation and manufacture of cell-based meat products. Focus areas included formulating cost-effective cell culture media, understanding cell line requirements, and envisioning new process templates for biomass generation and structured products.

Additionally, Dr. Schnitzler was Head of Cell Therapy Bioprocess R&D at MilliporeSigma, honing expertise in media optimization and single-use bioreactor systems for use in a complex regulatory environment. She also held technical and marketing roles supporting small-scale chromatography devices and cell culture products for monoclonal antibody production.

Continue reading “Dr Aletta Schnitzler — CSO — TurtleTree Labs — Cell-Based Dairy Bio-Products For Health & Nutrition” | >

A mechanism that causes autism, schizophrenia, Alzheimer’s and other conditions and is shared by mutations in the genes ADNP and SHANK3 has been unraveled by Tel Aviv University researchers who developed an experimental drug they found to be effective in animal models.

The drug could also be suitable for treating a range of rare syndromes that impair brain functions, said the scientists. The researchers were led by Prof. Illana Gozes from the Department of Human Molecular Genetics and Biochemistry at TAU’s Sackler Faculty of Medicine and the Sagol School of Neuroscience. The experimental drug, called Davunetide, had previously been developed in her lab.

The paper, which the team called a “scientific breakthrough,” was published in the scientific journal Molecular Psychiatry under the title “SH3-and actin-binding domains connect ADNP and SHANK3, revealing a fundamental shared mechanism underlying autism.”

Read more | >

“Spacecraft antenna designs are challenging due to their conflicting requirements for high gain, wide bandwidth, and low weight,” Mitsubishi announced. “High gain and wide bandwidth necessarily require a large aperture, but economical orbital deployment conventionally dictates that designs be lightweight and small enough to fit or fold inside a launch vehicle or satellite deployment mechanism.”

Mitsubishi also claimed that, with its new technology, ‘additive-manufacturing in space has now become possible.’ However, it’s worth noting that the International Space Station already features a 3D printer launched to the orbital station back in 2014. The European Space Agency also announced last year it would experiment with 3D printing in space using scrap metals from the Moon.

Still, the company’s new method has the potential to reduce the cost of satellite launches significantly, and it could pave the way for the construction of other vital parts for future space missions.

Read more | >